Study population: Patients with histologically proven non-signet cell synchronous or metachronous PMCRC, without systemic metastases, who are candidate for CRS + HIPEC (PCI score ≤20), and in whom (nearly) complete cytoreduction (CC-0 or CC-1) seems feasible.